{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T18:54:01Z","timestamp":1785351241989,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-025-01001-5","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T14:13:13Z","timestamp":1748614393000},"page":"659-664","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A case of IgA nephropathy associated with Crohn\u2019s disease treated with enteric-coated budesonide"],"prefix":"10.1007","volume":"14","author":[{"given":"Ryuto","family":"Yoshida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashin","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4809-5788","authenticated-orcid":false,"given":"Tatsuhiko","family":"Azegami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"1001_CR1","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.34067\/KID.0002382022","volume":"3","author":"L Sanchez-Russo","year":"2022","unstructured":"Sanchez-Russo L, Rajasekaran A, Bin S, Faith J, Cravedi P. The gut and kidney crosstalk in immunoglobulin a nephropathy. Kidney. 2022;3:1630\u20139.","journal-title":"Kidney"},{"key":"1001_CR2","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM199409293311303","volume":"331","author":"GR Greenberg","year":"1994","unstructured":"Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide for active Crohn\u2019s disease. Canadian inflammatory bowel disease study group. N Engl J Med. 1994;331:836\u201341.","journal-title":"N Engl J Med"},{"key":"1001_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","volume":"103","author":"J Barratt","year":"2023","unstructured":"Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH, NefIgArd Trial Investigators. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103:391\u2013402.","journal-title":"Kidney Int"},{"key":"1001_CR4","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, Floege J, Tesa\u0159 V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J, NefIgArd Trial Investigators. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402:859\u201370.","journal-title":"Lancet"},{"key":"1001_CR5","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S0140-6736(98)03563-6","volume":"353","author":"C Pozzi","year":"1999","unstructured":"Pozzi C, Bolasco PG, Fogazzi GB, Andrulli S, Altieri P, Ponticelli C, Locatelli F. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883\u20137.","journal-title":"Lancet"},{"key":"1001_CR6","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2215\/CJN.0000000000000457","volume":"19","author":"T Nakayama","year":"2024","unstructured":"Nakayama T, Kaneko H, Okada A, Suzuki Y, Fujiu K, Takeda N, Morita H, Takeda N, Fukui A, Yokoo T, Yasunaga H, Nangaku M, Hayashi K. Association of inflammatory bowel disease with incident IgA nephropathy. Clin J Am Soc Nephrol. 2024;19:704\u201311.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1001_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1681\/ASN.2020060848","volume":"32","author":"J Rehnberg","year":"2021","unstructured":"Rehnberg J, Symreng A, Ludvigsson JF, Emilsson L. Inflammatory bowel disease is more common in patients with iga nephropathy and predicts progression of ESKD: a swedish population-based cohort study. J Am Soc Nephrol. 2021;32:411\u201323.","journal-title":"J Am Soc Nephrol"},{"key":"1001_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s10038-019-0699-9","volume":"65","author":"D Shi","year":"2020","unstructured":"Shi D, Zhong Z, Wang M, Cai L, Fu D, Peng Y, Guo L, Mao H, Yu X, Li M. Identification of susceptibility locus shared by IgA nephropathy and inflammatory bowel disease in a Chinese Han population. J Hum Genet. 2020;65:241\u20139.","journal-title":"J Hum Genet"},{"key":"1001_CR9","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001437","volume":"11","author":"C Larson","year":"2024","unstructured":"Larson C, Munir N, Rao P, Farkash E, Kathuria P, Romain D, Berinstein J. Crohn\u2019s disease associated with IgA nephropathy effectively treated with the interleukin-23 inhibitor risankizumab. ACG Case Rep J. 2024;11: e01437.","journal-title":"ACG Case Rep J"},{"key":"1001_CR10","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12328-009-0112-x","volume":"2","author":"Y Ueno","year":"2009","unstructured":"Ueno Y, Tanaka S, Onitake T, Hanaoka R, Yoshioka K, Ito M, Chayama K. Infliximab treatment for Crohn\u2019s disease in a patient with IgA nephropathy. Clin J Gastroenterol. 2009;2:380\u20133.","journal-title":"Clin J Gastroenterol"},{"key":"1001_CR11","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/ajkd.2001.27690","volume":"38","author":"O Hotta","year":"2001","unstructured":"Hotta O, Miyazaki M, Furuta T, Tomioka S, Chiba S, Horigome I, Abe K, Taguma Y. Tonsillectomy and steroid pulse therapy significantly impact on clinical remission in patients with IgA nephropathy. Am J Kidney Dis. 2001;38:736\u201343.","journal-title":"Am J Kidney Dis"},{"key":"1001_CR12","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/ndt\/gfu020","volume":"29","author":"T Kawamura","year":"2014","unstructured":"Kawamura T, Yoshimura M, Miyazaki Y, Okamoto H, Kimura K, Hirano K, Matsushima M, Utsunomiya Y, Ogura M, Yokoo T, Okonogi H, Ishii T, Hamaguchi A, Ueda H, Furusu A, Horikoshi S, Suzuki Y, Shibata T, Yasuda T, Shirai S, Imasawa T, Kanozawa K, Wada A, Yamaji I, Miura N, Imai H, Kasai K, Soma J, Fujimoto S, Matsuo S, Tomino Y, Special IgA Nephropathy Study Group. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546\u201353.","journal-title":"Nephrol Dial Transplant"},{"key":"1001_CR13","doi-asserted-by":"publisher","first-page":"18455","DOI":"10.1038\/s41598-023-45514-4","volume":"13","author":"T Kawamura","year":"2023","unstructured":"Kawamura T, Hirano K, Koike K, Nishikawa M, Shimizu A, Joh K, Katafuchi R, Hashiguchi A, Matsuzaki K, Maruyama S, Tsuboi N, Narita I, Yano Y, Yokoo T, Suzuki Y. Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy. Sci Rep. 2023;13:18455.","journal-title":"Sci Rep"},{"key":"1001_CR14","first-page":"CD000296","volume":"6","author":"A Rezaie","year":"2015","unstructured":"Rezaie A, Kuenzig ME, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH, Kaplan GG, Seow CH. Budesonide for induction of remission in Crohn\u2019s disease. Cochrane Database Syst Rev. 2015;6:CD000296.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"1001_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s13730-023-00836-0","volume":"13","author":"A Shimizu","year":"2024","unstructured":"Shimizu A, Tsuboi N, Haruhara K, Shirai I, Ogawa K, Miura A, Oshiro K, Ueda H, Yokote S, Okabe M, Sasaki T, Ikeda M, Yokoo T. Active flare of IgA nephropathy during long-term therapy with anti-tumor necrosis factor-\u03b1 antibody drugs for Crohn\u2019s disease: three case reports and literature review. CEN Case Rep. 2024;13(4):249\u201357.","journal-title":"CEN Case Rep"},{"issue":"5","key":"1001_CR16","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1093\/rheumatology\/keab662","volume":"61","author":"C Rasmussen","year":"2022","unstructured":"Rasmussen C, Abitbol V, El Karoui K, Bourrier A, Paule R, Vuitton L, Maurier F, Laharie D, Fum\u00e9ry M, Agard C, Collins M, Nancey S, Rafat C, Kervegant AG, Queyrel-Moranne V, Moulis G, Pigneur B, R\u00e9gent A, Gay C, Morbieu C, Durel CA, Ducloux D, Aubin F, Voicu M, Joher N, Szwebel T, Martinez-Vinson C, Koch S, Guillevin L, Peyrin-Biroulet L, Terrier B. IgA vasculitis in patients with inflammatory bowel disease: new insights into the role of TNF-\u03b1 blockers. Rheumatology (Oxford). 2022;61(5):1957\u201365.","journal-title":"Rheumatology (Oxford)"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-025-01001-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-025-01001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T16:30:09Z","timestamp":1757176209000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-025-01001-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":16,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["1001"],"URL":"https:\/\/doi.org\/10.1007\/s13730-025-01001-5","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted according to the Declaration of Helsinki guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Informed and written signed consent was provided by the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}